The company is implementing a number of projects focused on developing "next-in-class" and "first-in-class" pharmaceuticals in its priority therapeutic areas—treatment of infectious diseases, parenteral nutrition, and phthisiology. Funding is provided through both internal resources and external investments. In collaboration with partners—leading medical research and healthcare institutions—PJSC "Kraspharma" aims to achieve results in a shorter time frame, gradually replacing "outdated" drugs in its product portfolio with new, more effective, and safer medications.

The Company’s innovation development strategy includes the following areas:
• Development of methods to enhance the activity of antimicrobial chemotherapeutic agents, primarily through the "protection" of the beta-lactam antibiotic molecule by combining it with one of the beta-lactamase inhibitors. The relevance and demand for such methods are undeniable: it is well known that beta-lactamase enzymes produced by bacteria are a major cause of widespread microbial resistance and the resulting ineffectiveness of therapy.
• Research into new antiseptics aimed at developing effective new medications for the local treatment and prevention of wound infections. A first and significant step in this direction has already been taken: the medicinal product Meporan has completed preclinical studies and the first stage of clinical trials.
• Study and clinical testing of new dosage forms of anti-tuberculosis chemotherapeutic agents to improve the effectiveness of treatment for severe forms of tuberculosis.
• Introduction of new balanced, effective, and safe parenteral nutrition products into clinical practice. Today, the Company’s portfolio includes its own unique development—Haimix, an amino acid mixture for parenteral nutrition that has successfully passed all required preclinical and clinical protocols.